Ziopharm Comments on Delay of WaterMill’s Stated Consent Deadline
December 11, 2020 18:57 ET
|
ZIOPHARM Oncology Inc
Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today...
Egan-Jones Recommends Against Electing Dissident’s Full Slate of Nominees to Ziopharm Board
December 10, 2020 19:01 ET
|
ZIOPHARM Oncology Inc
Recommends Against Electing WaterMill Nominee Jaime Vieser Ziopharm Continues to Recommend that Shareholders Support Company’s Strong Progress by Returning the GREEN Consent Revocation Card ...
Ziopharm Details Actions in Response to Shareholder Feedback
December 04, 2020 08:30 ET
|
ZIOPHARM Oncology Inc
Has Held Several Discussions with WaterMill to Reach an Amicable Resolution to Consent Solicitation Board Accepts Resignation of Director Elan Ezickson Reiterates...
Ziopharm Comments on Institutional Shareholder Services’ Recommendation to Reject WaterMill’s Attempt to Remove Half of Ziopharm’s Board of Directors
November 27, 2020 17:32 ET
|
ZIOPHARM Oncology Inc
ISS Acknowledges Ziopharm’s Outperformance of its Peer Group During Chairman Scott Tarriff’s Tenure Court Filings Raise Concerns About Professional Past of WaterMill Nominee Holger Weis Ziopharm...
Ziopharm Releases Investor Presentation Highlighting Execution of Strategy and Substantial Board Refreshment to Enhance Shareholder Value
November 20, 2020 11:00 ET
|
ZIOPHARM Oncology Inc
Continues to Execute on Strategy to Ensure Strong Long-Term Outlook Outlines Additions of Five Highly Qualified Industry Veterans to Board Over the Last 18 Months BOSTON, Nov. 20, 2020 (GLOBE...
Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Glioblastoma and DIPG at the 2020 Society for Neuro-Oncology Annual Meeting
November 19, 2020 09:00 ET
|
ZIOPHARM Oncology Inc
– First Data from Ongoing Phase 2 Study of Controlled IL-12 in Combination with Cemiplimab Demonstrate Promising Safety Profile in rGBM, and a Confirmed Partial Response – – Updated Interim Data...
Ziopharm Oncology Appoints Raffaele Baffa, M.D., Ph.D., as Chief Medical Officer
November 17, 2020 16:15 ET
|
ZIOPHARM Oncology Inc
– Pharmaceutical Executive with 20+ Years of Experience Across All Phases of Clinical Research Including IND Submissions, Trial Design and Regulatory Filings – – Former Chief Medical Officer for...
Ziopharm Oncology Appoints Mary Thistle to Board of Directors
November 16, 2020 08:30 ET
|
ZIOPHARM Oncology Inc
– Special Advisor and Former Chief of Staff for the Bill & Melinda Gates Medical Research Institute Joins as Independent Director – – Biotechnology Leader with 25+ Year Track Record of Creating...
Ziopharm Oncology to Participate in Jefferies Virtual London Healthcare Conference on November 19, 2020
November 13, 2020 09:15 ET
|
ZIOPHARM Oncology Inc
BOSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate...
Ziopharm Oncology Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 05, 2020 16:02 ET
|
ZIOPHARM Oncology Inc
– Company plans to file IND for Ziopharm TCR-T program in Q1 of next year for its Library “hotspot” trial – – Eden BioCell on track for IND filing in Taiwan for autologus CAR-T clinical trial this...